The Archive · A Source

ESMO 2024: Over Half of Advanced Melanoma Patients Survive 10 Years with Combination Immunotherapy

Institute of Cancer Research ESMO 2024 www.icr.ac.uk/about-us/icr-news/detail/over-half-of-advanced-melanoma-patients-treated-with-combination-immunotherapy-survive-the-disease-for-at-least-10-years